Scientists find new drug target for hard-to-treat leukaemia

March 30, 2012

(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research published in Cancer Cell today.

The team at the Paterson Institute for Cancer Research at The University of Manchester have identified a new drug target – an enzyme called LSD1 – for an aggressive form of acute called mixed lineage leukaemia (MLL).  LSD1 helps control whether certain cancer-causing genes are turned on or off. Blocking the enzyme prevents the production of proteins that drive the cancer.   

Scientists at Cancer Research UK’s Paterson Drug Discovery Unit synthesised molecules to block this enzyme, and lead author Dr Tim Somervaille, group leader at Cancer Research UK’s Leukaemia Biology Laboratory, showed that they could stop the growth of leukaemia cells – taken from patients with the disease, and also from mice.

Every year in the UK around 2,380 people are diagnosed with acute myeloid leukaemia and of these it is estimated that around five percent – around 120 patients – have the MLL subtype.

Survival for acute myeloid leukaemia remains low although it has improved. Currently, around forty percent of people aged under 60 with the MLL-AF9 subtype survive the disease for five years or more.

Dr Somervaille said: “It’s difficult to successfully treat patients with this type of leukaemia. There aren’t any targeted drugs available and many patients can’t be cured with current treatments, such as intensive chemotherapy and bone marrow transplantation.  So there’s an urgent need for new drugs.

“We’re very pleased to have tested molecules that homes in on an enzyme called LSD1 in a completely new approach to stop the growth of this disease. And we also believe this target may be important in a range of other types of cancer, but more research is needed.  

“The next stage is to develop molecules like this one further, and run clinical trials to see if they could be used to treat patients in the future.”

Dr Julie Sharp, Research UK’s senior science information manager, said: “It’s great news that this molecule could provide a new targeted way to treat an aggressive type of leukaemia, for which treatment options are limited.

“Our scientists have been at the heart of progress that has seen great improvements in the treatment of leukaemia. For example, we developed some of the first important drugs for blood cancers and pioneered treatment with radiotherapy. And we’ve revealed many of the gene changes that fuel the development and growth of blood cancers, paving the way for future treatments.

“But there is much more to be done and, only with continued public support, can our scientists around the UK continue their groundbreaking research into leukaemia to learn more about the biology of the disease – and improve survival.”

Explore further: Scientists discover how to beat resistance to standard leukaemia drug

More information: Harris, W. et al (2012). The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells Cancer Cell DOI: 10.1016/j.ccr.2012.03.014

Related Stories

Scientists discover how to beat resistance to standard leukaemia drug

December 9, 2011
(Medical Xpress) -- Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according ...

Cancer Research UK launches trial of new drug to treat acute childhood leukaemia

January 27, 2012
Cancer Research UK’s Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment.

Stem cell treatment to prevent leukemia returning is a step closer, say scientists

June 2, 2011
Researchers at King's College London have identified a way of eliminating leukaemic stem cells, which could lead to new treatments that may enable complete remission for leukaemia patients. An early study in mice has shown ...

Key cause of bone marrow failure identified

May 3, 2011
(Medical Xpress) -- Researchers funded by Leukaemia & Lymphoma Research and the Medical Research Council (MRC) have identified one of the first steps that can cause bone marrow failure and eventually lead to blood cancers. ...

Blood vessel 'inflator' could be 'game-changer' for pancreatic cancer treatment

March 21, 2012
(Medical Xpress) -- Cancer Research UK scientists have shown that an enzyme can re-expand the insides of blood vessels allowing more drugs and large antibody molecules to reach pancreatic tumors, according to research published ...

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.